Iganidipine

Iganidipine是一种钙离子通道拮抗剂。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥8350.00

6680.00

- +
5mg

￥16525.00

13220.00

- +
10mg

￥28075.00

22460.00

- +
20mg

￥49587.00

39670.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Iganidipine is a Ca2+ antagonist.

Iganidipine (0.03% solution) significantly increases optic nerve head (ONH) tissue blood velocity (NBONH) by 8 to 10% in treated eyes after a single administration (p<0.05) or by 18 to 35% after 7-, 14-, or 21-day twicedaily administration in rabbits (p<0.05). In monkeys, 0.03% and 0.1% Iganidipine significantly increases NBONH in treated eyes by 20 and 41% after 7-day (p<0.05) twice-daily administration, respectively[1].

[1]. Ishii K, et al. Iganidipine, a new water-soluble Ca2+ antagonist: ocular and periocular penetration after instillation. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1169-77.

Protocol

Animal experiment:

Monkeys[1] Five adult cynomolgus monkeys (age, 5-8 years; weight, 3-5 kg; sex, 5 males) are used. All examinations are performed with the monkeys sitting in a modified monkey chair. On the first experimental day, after general anesthesia is induced by Ketamine hydrochloride at a dose of 8 to 10 mg/kg intramuscularly, pupil dilation is induced with one drop of Tropicamide in both eyes. The NBONH, IOP, blood pressure, pulse rate, SaO2, and body temperature are measured at 9AM. Starting on the 2nd experimental day, Iganidipine (0.03% or 0.1%, 30 mL) is administered in one randomly chosen eye and vehicle solution into the other eye twice daily at 8AM and 8PM for 7 days. At 9AM on the 8th experimental day, the same measurements are repeated after general anesthesia and bilateral pupil dilation. After a 4-week interval, a second series of experiments is performed using a different Iganidipine concentration according to the same time schedule.

参考文献:

[1]. Ishii K, et al. Iganidipine, a new water-soluble Ca2+ antagonist: ocular and periocular penetration after instillation. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1169-77.